SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 152 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is 0.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $62 | -99.9% | 3,688 | -10.0% | 0.00% | 0.0% |
| Q3 2022 | $70,000 | 0.0% | 4,098 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $70,000 | 0.0% | 4,098 | 0.0% | 0.00% | +100.0% |
| Q1 2022 | $70,000 | +2233.3% | 4,098 | +1889.3% | 0.00% | – |
| Q2 2021 | $3,000 | 0.0% | 206 | -17.6% | 0.00% | – |
| Q1 2021 | $3,000 | -25.0% | 250 | -7.1% | 0.00% | – |
| Q4 2020 | $4,000 | +300.0% | 269 | +31.9% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 204 | +30.8% | 0.00% | – |
| Q2 2020 | $1,000 | 0.0% | 156 | 0.0% | 0.00% | – |
| Q1 2020 | $1,000 | 0.0% | 156 | 0.0% | 0.00% | – |
| Q4 2019 | $1,000 | 0.0% | 156 | -1.9% | 0.00% | – |
| Q3 2019 | $1,000 | -87.5% | 159 | -68.2% | 0.00% | – |
| Q3 2018 | $8,000 | +300.0% | 500 | +316.7% | 0.00% | – |
| Q2 2018 | $2,000 | 0.0% | 120 | +7.1% | 0.00% | – |
| Q1 2018 | $2,000 | 0.0% | 112 | 0.0% | 0.00% | – |
| Q4 2017 | $2,000 | 0.0% | 112 | +6.7% | 0.00% | – |
| Q3 2017 | $2,000 | – | 105 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rokos Capital Management LLP | 6,474,348 | $11,394,852 | 0.84% |
| WASATCH ADVISORS LP | 13,642,417 | $24,010,654 | 0.15% |
| Avidity Partners Management LP | 2,470,000 | $4,347,200 | 0.14% |
| Acrisure Capital Management, LLC | 75,832 | $133,464 | 0.14% |
| Golden State Equity Partners | 135,765 | $238,946 | 0.13% |
| Long Focus Capital Management, LLC | 1,072,000 | $1,886,720 | 0.11% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $78,008 | 0.10% |
| CAXTON ASSOCIATES LP | 288,218 | $507,264 | 0.08% |
| XTX Topco Ltd | 206,334 | $363,148 | 0.08% |
| Rhenman & Partners Asset Management AB | 314,157 | $534,067 | 0.06% |